Please assess the completion status of the following clinical trial:

Trial Title: Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML) in accelerated phase or blast crisis, chronic lymphocytic leukemia (CLL), Non-Hodgkin lymphoma (NHL), myelodysplastic syndromes (MDS) (intermediate-2 or high-risk disease by International Pelvic Pain Society \[IPPS\])~* Patients with AML, ALL, or MDS scheduled for myeloablative conditioning should have =\< 10% blasts in bone marrow or peripheral blood at the start of conditioning~* Patients with AML, ALL, or CML scheduled for reduced intensity conditioning or non-myeloablative conditioning should be in complete morphologic remission at the start of conditioning (residual disease by flow cytometry or cytogenetics and/or incomplete recovery of neutrophil or platelet count are acceptable)~* Patients with CLL or NHL scheduled for reduced intensity or non-myeloablative conditioning should have no evidence of bulky disease (\> 50% bone marrow involvement or masses \> 10 cm) at the start of conditioning~* Fulfills all pulmonary, cardiac, renal, and hepatic criteria for standard-of-care matched unrelated donor (MUD) allogeneic HCT~* Men and women of reproductive potential must agree to use an acceptable method of birth control during treatment and for twelve months after stem cell transplantation~* Adequately matched unrelated donor available~* Written informed consent; written informed consent of the unrelated donor is required to participate in the optional studies~Exclusion Criteria:~* Patient or donor infected with human immunodeficiency virus (HIV)~* Patient or donor with history of hepatitis B or C and/or positive serology consistent with previous hepatitis B or C infection (patients and/or donor who received Hepatitis B vaccination are acceptable)~* Patient or donor with active hepatitis B or C and/or detectable viral ribonucleic acid (RNA)~* More than 20,000 circulating CD20+ cells/uL~* Treatment with rituximab for any reason in the 12 months preceding HCT~* Patient scheduled for cord blood transplantation~* Presence of active uncontrolled infection at start of conditioning~* Presence of active central nervous system (CNS) disease (history of adequately treated CNS disease is acceptable)~* Presence of uncontrolled psychiatric disorder~* Patient unable to give informed consent~* Unrelated donor products received from the Deutsche Knochenmarkspenderdatei (DKMS) Registry are not eligible for the optional study

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (Rituximab and allogeneic HCT transplant) (Type: EXPERIMENTAL): CONDITIONING REGIMEN: Patients receive one of the following conditioning regimens as per the transplant physician: cyclophosphamide and TBI; targeted busulfan and fludarabine; reduced-dose busulfan and fludarabine; or fludarabine and TBI.~GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS: Patients receive rituximab IV on days -6, 1, 8, and 15 and anti-thymocyte globulin IV over 6-8 hours on days -3 to -1. Patients also receive tacrolimus IV continuously and then PO beginning on day -1 and continuing until day 150 followed by a taper until day 180 and mycophenolate mofetil PO or IV twice daily on days -1 to 60.~TRANSPLANTATION: Patients undergo allogeneic hematopoietic stem cell transplantation on day 0.

Based on this trial design, predict the completion outcome and termination type (if applicable).